The European Cardiovascular therapeutics drugs market size stood at USD 30.46 billion in 2020 and is expected to rise to USD 35.83 billion by the end of 2028 exhibiting a CAGR of approximately 2.05% during the forecast period.
Cardiovascular disease is the most common cause of death and among the most frequent sources of disability in Sweden. They amount to 35% of the total Non-Communicable disease mortality. They are a group of disorders that occur in the heart and blood vessels. The major reasons include heart failure, blood clots, coronary artery diseases and increased cholesterol. With cardiovascular diseases being the most common cause of morbidity and mortality, the market has gained a tremendous value that will continue to grow in the years to come. This presents numerous opportunities in terms of investments to the organizations that excel in the field of developing newer drugs that are best suited to the patients.
Cardiovascular Therapeutics drugs market in Sweden is mainly driven by the increase in prevalence of Cardiovascular diseases owing to the rise of geriatric population. This is directly associated with delayed mortality due to development in healthcare services offered to the people of Sweden.
The market is also driven by the rise in risk factors like obesity, increased physical inactivity, smoking and other harmful lifestyle factors. The rise in per capita spending on healthcare services by the people of Sweden also drives the market for Cardiovascular therapeutic drugs.
A general increase in awareness regarding the cardiovascular diseases and their complications have paved the way for timely diagnosis and care which in turn drive the drug market.